alan franciscus executive director, hepatitis c support project editor-in-chief, hcv advocate— ...
TRANSCRIPT
![Page 1: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/1.jpg)
Alan FranciscusExecutive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate—www.hcvadvocate.org
Editor-in-Chief, HBV Advocate –www.hbvadvocate.org
Follow us on Twitter and Facebook:hcvadvocatehbvadvocate
Hepatitis C and HIV/HCV Coinfection
www.hcvadvocate.org
![Page 2: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/2.jpg)
•OVERVIEW OF HEPATITIS C • Please hold questions until the end of the first session
•HIV AND HEPATITIS C – DIFFERENCES AND SIMILARITIES
•HIV AND HEPATITIS COINFECTION
•NEW ADVANCES IN HEPATITIS C CARE
Agenda
www.hcvadvocate.org
![Page 3: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/3.jpg)
•HCV STATISTICS
•HCV DIAGNOSTICS
•HCV TRANSMISSION & PREVENTION
•HCV SYMPTOMS, DISEASE PROGRESSION, MANAGEMENT
•HCV TREATMENT
Hepatitis C Overview
www.hcvadvocate.org
![Page 4: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/4.jpg)
Hepatitis C Statistics
U.S. Population1.6% overall
~4 million Americans infected
3.2 million chronically infected
2.1% Mexican Americans
3.4% African Americans
www.hcvadvocate.org
![Page 5: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/5.jpg)
Hepatitis C Statistics - Montana
Montana 967, 440 x 1.6% = ~15,500 people with HCV
in Montana
948 case of hepatitis C (chronic and acute) reported in 2008 Compare to HIV – 895 cases reported since 1985
Highest rates seen in American Indians and persons age 45-54 (2008)
www.hcvadvocate.org
![Page 6: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/6.jpg)
HCV Diagnostics: Antibody tests
• HCV Elisa (EIA)
• Most common antibody test
• A positive antibody test indicates exposure
• It does not indicate current hepatitis C infection
• Orasure HCV Antibody Test – more laterwww.hcvadvocate.org
![Page 7: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/7.jpg)
HC V Diagnostics: Viral Load Tests
Viral Load tests PCR and TMA 5-10 IU/mL HCV RNA by branched DNA Assay – > 500 IU/mL
Why Is a Viral Load Test Important? To confirm active infection Helps to predict treatment response Indication that treatment is working
** Viral load does not correlate with disease progression**
www.hcvadvocate.org
![Page 8: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/8.jpg)
HCV Diagnostics: Genotype Test
Genotypes (1,2,3,4,5,6) U.S. population
70% genotype 1 30% genotypes 2 & 3
Why Is a Genotype Test Important? Helps predict treatment response Dictates treatment duration of 24 or 48
weeks
www.hcvadvocate.org
![Page 9: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/9.jpg)
HCV Diagnostics: Liver Biopsy
Gold Standard for Determining the Health of the Liver
Measure of inflammation
Extent of scarring (if any)
Non-invasive methods – not as accurate
www.hcvadvocate.org
![Page 10: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/10.jpg)
Transmission & Prevention
Shared Needles
All Drug Paraphernalia
Blood Before 1992 - transfused, products, procedures
Sexual Transmission(1-3%)
Healthcare Workers – needle sticks
Shared House-hold items – razors & toothbrushes
Mother to Child <5%
Tattoos / Piercing
<10% of routes can not be identified
www.hcvadvocate.org
![Page 11: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/11.jpg)
Transmission & Prevention
HCV is not spread by breast feeding, sharing eating utensils or drinking glasses, kissing, hugging
Direct blood to blood transmission route
www.hcvadvocate.org
![Page 12: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/12.jpg)
Transmission & Prevention: Tips
Injection and Non-Injection Drugs
Do not share needles, cookers, cottons, straws, pipes or any items that might come into contact with blood
Use bleach to clean
People in Stable Long-Term Monogamous Sexual Relationships CDC – no need to change current sexual practices –
but there is a risk
www.hcvadvocate.org
![Page 13: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/13.jpg)
Transmission & Prevention: Tips
Safer Sex For so called “high risk groups”
Multiple sexual partners, people with sexually transmitted diseases, coinfection with HIV or HBV
Any situation where blood is present
www.hcvadvocate.org
![Page 14: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/14.jpg)
Transmission & Prevention: Tips
Mother to Child Transmission Low risk – about 5-6% Given the low rate of transmission, pregnancy
should not be avoided. Note: pregnant women can not take interferon
or ribavirin
Health-Care Settings Follow standard/universal precautions
www.hcvadvocate.org
![Page 15: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/15.jpg)
Transmission & Prevention: Tips
Tattoos & Piercing
Considered a low risk in commercial setting
Make sure disposable needles and separate ink pots are used and that general safety precautions are followed
Considered a higher risk in other settings Non-commercial settings such as in prison or
on the streets
www.hcvadvocate.org
![Page 16: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/16.jpg)
Household Cover cuts or sores Do not share personal hygiene items
(toothbrushes, razors, etc.)
Professional Personal Care Settings Standard precautions Disposable equipment Bring own equipment
www.hcvadvocate.org
HCV Transmission & Prevention: Tips
![Page 17: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/17.jpg)
Chronic Symptoms
Fatigue – mild to severe
Flu-like symptoms (muscle/joint/fever)
‘Brain Fog’
Liver pain
Loss of appetite
Headaches
Gastro problems
and more……
www.hcvadvocate.org
![Page 18: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/18.jpg)
HCV Disease Progression
10-25% of HCV positive people progress on to serious disease over 10-40 years
Fibrosis Light scarring
Cirrhosis Compensated vs. decompensated
Steatosis Fatty deposits in the liver
www.hcvadvocate.org
![Page 19: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/19.jpg)
Disease Progression: Managing Hepatitis C
Regular medical monitoring
Get vaccinated – Hep A & Hep B
Healthy balanced diet www.mypyramid.gov
Exercise
Stress Reduction
Support Groups
Alcohol – Avoid or reduce
www.hcvadvocate.org
![Page 20: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/20.jpg)
HCV Treatment
What is interferon? General antiviral – immune booster
By injection
What is ribavirin? Antiviral
Used only in combination with interferon Pill or capsule
www.hcvadvocate.org
![Page 21: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/21.jpg)
Treatment - Standard of Care
Merck/Schering – PEG-Intron + Rebetol (800mg) Genotype 1- 41% SVR (48 weeks)
Genotypes 2 thru 6 – 75% (48 weeks)
Genentech/Roche – Pegasys + Copegus (1000-1200 mg) Genotype 1 – 44-51% SVR (48 weeks)
Genotypes 2 & 3 – 82% SVR (24 weeks) Genotypes 2 thru 6 – 70% SVR (48 weeks)
*FDA Package Insert
www.hcvadvocate.org
![Page 22: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/22.jpg)
Side-effects
Interferon Fatigue Muscle/Joint pain Nausea Headaches Anxiety Depression Dry Skin/Rashes And more…..
Ribavirin seems to make
interferon side effects worse – especially fatigue – Anemia
**(both men & women must use birth control)
www.hcvadvocate.org
![Page 23: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/23.jpg)
Managing Side-Effects
Inject before bedtime
Drink lots of water
Low doses of ibuprofen or acetaminophen
Pain medications
Small frequent meals
Light exercise
Daily moisturizing
Vary injection sites
Anti-Depressants
Plenty of rest
Key: support from medical providers, family, friends, work – all areas of life
www.hcvadvocate.org
![Page 24: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/24.jpg)
Complementary Medicine
Herbs – milk thistle, licorice root, etc. Always check with your doctor and herbalist – some
herbs are unsafe
Acupuncture / Acupressure
Traditional Chinese Medicine
www.hcvadvocate.org
![Page 25: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/25.jpg)
HIVHIV HCVHCV
Single stranded RNA
Retrovirus
Integrates into DNA
Single stranded RNA
Flavivirus
Does not integrate
into DNA
Comparisons
www.hcvadvocate.org
![Page 26: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/26.jpg)
HIVHIV HCV HCV
Mainly infects CD 4 cells
Daily – replicates billions
High mutation rate
Mainly infects liver cells
Daily – replicates trillions
Very high mutation rate
Comparisons
www.hcvadvocate.org
![Page 27: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/27.jpg)
HIV HIV HCV HCV
Chronic – 100%
US – 1 major strain
High sexual transmission rate
High IDU transmission rates (Blood)
Chronic rates - 55-85%
US – 3 major strains
Low Sexual transmission rate
Very high IDU transmission rates (Blood)
Comparisons
www.hcvadvocate.org
![Page 28: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/28.jpg)
HIVHIV HCV HCV
Cure? No
Treatment - lifelong
Can become resistant
Cure? Virological Cure
Treatment 24 to 48 weeks
No resistant issues yet New direct antivirals
will lead to resistance
Comparisons – Con’t
www.hcvadvocate.org
![Page 29: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/29.jpg)
HIV HIV HCV HCV
U.S. –
~1,000,000
U.S. –
~4,000,000
Comparisons – Prevalence
www.hcvadvocate.org
![Page 30: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/30.jpg)
Guidelines for Prevention of Opportunistic Infections
HIV – Infected persons should be screened for HCV
Patients should be advised on alcohol usePatients should be screened for HAV & HBV if
negative, they should be vaccinatedPatients should be evaluated for liver disease
and possible need for treatmentLiver enzymes should be monitored after
initiation of HAART
*U.S. Public Health Service and the Infectious Disease Society of Americawww.hcvadvocate.org
![Page 31: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/31.jpg)
•Transmission / Prevention
•Diagnosing HCV
•HCV Disease Progression
•HCV Treatment Response
Hepatitis C vs. HIV/HCV Coinfection
www.hcvadvocate.org
![Page 32: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/32.jpg)
HCVHCV HIV/HCV Coinfection HIV/HCV Coinfection
Sexual transmission is low (0-3%)
Mother-to-Child Transmission ~5-6% HCV meds can cause
birth defects
Sexual transmission is higher ~ 15-25%
Mother-to-Child Transmission ~25% HCV meds can cause
birth defects
HCV Transmission
www.hcvadvocate.org
![Page 33: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/33.jpg)
Hepatitis C Hepatitis C HIV/HCV Coinfection HIV/HCV Coinfection
Antibody Test
HCV Viral load to confirm active infection
Antibody Test Note: If low cd4 cell
count use HCV RNA
HCV RNA to confirm active infection
Diagnosing HCV
www.hcvadvocate.org
*People with a comprised immune system may not develop HCV antibodies
![Page 34: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/34.jpg)
Hepatitis C Hepatitis C HIV/HCV Coinfection HIV/HCV Coinfection
Slow rate of disease progression – usually over 10, 20, 30 years
Faster rate of disease progression to cirrhosis – up to 2-3 times faster & can occur in as little as 10 years
HCV coinfection is the leading cause of death among people with HIV
HCV Disease Progression
www.hcvadvocate.org
![Page 35: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/35.jpg)
Does HCV Make HIV Worse?
Still a controversial issue but most experts do not believe that HCV makes HIV worse
HCV may blunt immune reconstitution
www.hcvadvocate.org
![Page 36: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/36.jpg)
Does HIV Make HCV Worse?
HIV accelerates HCV disease progression – doubles the risk for cirrhosis and increases the chance for liver cancer
Some evidence suggests that when HIV is stable – HCV disease progression is slowed in people with HIV/HCV coinfection
www.hcvadvocate.org
![Page 37: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/37.jpg)
When and Which to Treat?
Generally, HIV should be under control Most recommend treat HIV first
HCV – People with HIV/HCV should be considered for HCV treatment Unless:
CD4 counts less than 200 Active opportunistic illness
www.hcvadvocate.org
![Page 38: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/38.jpg)
HIV Meds and the Liver
Generally, some medications including HIV medications can be difficult for a liver to process
HIV meds temporarily increase liver
enzymes and HCV viral load – usually stabilize over time If ALT’s 4 to 5 times baseline –
Change to more liver friendly HIV medications
www.hcvadvocate.org
![Page 39: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/39.jpg)
Recommendations
HIV specialist and liver specialist should closely follow co-infected people
Monitor liver functions especially when on HIV treatment
Switch to more liver friendly HIV medications
www.hcvadvocate.org
![Page 40: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/40.jpg)
HCV Treatments
Treatment response rates lower in people with HIV Genotype 1 up to 29%; Genotype 2,3 up to 62%
Closely monitored for: Anemia rates up to 50% caused by ribavirin
Thrombocytopenia (low platelets) caused by interferon Neutropenia (low white blood cells) caused by
interferon
www.hcvadvocate.org
![Page 41: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/41.jpg)
Ribavirin and HIV Medications
Ribavirin originally developed for HIV, but not effective
HIV medications that should be avoided or used with caution when combined with ribavirin: D4T (Zerit) AZT (Retrovir) DDI (Videx)
www.hcvadvocate.org
![Page 42: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/42.jpg)
Psychological Impact
Two or more potentially life-threatening conditions
Lack of awareness
Lack of support
www.hcvadvocate.org
![Page 43: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/43.jpg)
HCV ORAQUICK RAPID HCV ANTIBODY TEST
Venous – whole blood only – clinics$20.00 ?
Available some time in 2010
Results in 20 minutes
Finger prick and oral swabFiling for marketing approval likely by end of 2010
Approval expected in 2011
Advances in HCV: Diagnostic Tools
www.hcvadvocate.org
![Page 44: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/44.jpg)
•THE BIOSENSOR - HANDHELD• Detect infections – HIV, Hepatitis, HINI, STI, Anthrax
• Tests blood, saliva, urine – the fluid is injected into a small hole in the device
• Runs on AA batteries - results in 5 seconds
• Developed by University of New Mexico and Sandia National Laboratories • Estimated cost - $5,000 device - $10.00 for chips – 2 years away?
Advances in HCV: Diagnostic Tools
www.hcvadvocate.org
![Page 45: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/45.jpg)
•IL28B• A variation in IL28B called CC genotype = 2-fold increase in response
• ~80% of those who achieved response (SVR) had CC genotype
• Partly explained SVR differences in African Americans and Hispanics
• Test commercially available in August 2010?
Advances in HCV: Treatment
www.hcvadvocate.org
![Page 46: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/46.jpg)
•HCV PROTEASE INHIBITORS• Telaprevir and boceprevir - genotype 1 - in combination with pegylated interferon and ribavirin
• Increase efficacy by 10 to 30%
• Treatment duration - response guided therapy
• Telaprevir – skin rash – may be whole body rash
• Boceprevir – higher rates of anemia
Advances in HCV : Treatment
www.hcvadvocate.org
![Page 47: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/47.jpg)
•MEDICATION BURDEN:• Telaprevir – every 8 hours
• Pegylated interferon (sq) once-a-week
• Ribavirin – taken twice a day • Adherence• Resistance
Advances in HCV: Treatment
www.hcvadvocate.org
![Page 48: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/48.jpg)
SOME UNANSWERED QUESTIONS – ARE ALL ORAL MEDICATIONS VIABLE?
PROBABLY A COMBINATION OF DIFFERENT HCV PROTEASE AND POLYMERASE INHIBITORS
AT LEAST 5 TO 10 YEARS AWAY
Advances in HCV: Oral Meds Only
www.hcvadvocate.org
![Page 49: Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate— Editor-in-Chief, HBV Advocate –](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649ce35503460f949af884/html5/thumbnails/49.jpg)
THANKS!
The End
www.hcvadvocate.org